Funding

Active Funding:

1R01HL145985: Mechanistic underpinnings of increased adipose tissue in HFpEF

Protocol # EFC15156:A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of SOtagLiflozin on Clinical Outcomes in HemOdynamIcally STable Patients. Sponsor: Sanofi. PI: Flora Sam, MD; funded 2018-2021

“A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Safety and Efficacy of Different Doses of IW-1973 over 12 Weeks in Patients with Heart Failure with Preserved Ejection Fraction (CAPACITY HFpEF )” – Sponsor: Ironwood Pharmaceuticals, Inc. PI: Flora Sam, MD; funded 2018-2019

Completed Funding:

5R01HL117153: Role of Aldosterone and Adiponectin in inter-tissue communication in Diastolic Heart Failure

American Heart Association (17POST33660439). Postdoctoral Fellowship to Dr. Valero-Munoz

5R01HL079099 – ROLE OF ALDOSTERONE IN CARDIAC REMODELING

3R01HL079099-04S1 – ROLE OF ALDOSTERONE IN CARDIAC REMODELING

1R21HL095891-01A1 – NOVEL INSIGHTS INTO THE PATHOGENESIS OF LIGHT CHAIN CARDIAC AMYLOIDOSIS

1R21HL102631-01 – FOLLISTATIN-LIKE 1 AND THE CARDIAC SECRETOME IN HUMAN HEART FAILURE

 

Do you want to join our team ?

Post-doctoral funding opportunities: For details visit: http://www.bumc.bu.edu/wci-training-programs

Pre-doctoral funding opportunities: For details visit: http://www.bumc.bu.edu/cardiograd/application/